Alexion NMOSD Treatment Patent - Anti-C5 Antibody Methods
Summary
The USPTO granted Patent US12612451B2 to Alexion Pharmaceuticals, Inc. on April 28, 2026, covering methods for treating neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody or antigen-binding fragment. The patent, filed December 8, 2020 as Application No. 17783106, contains 20 claims. Named inventors include Kerstin Allen, Marcus Yountz, Stephan Ortiz, and Fanny O'Brien.
“Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.”
About this source
Granted patents in USPTO classification C07K, covering peptides, proteins, antibodies, and related biological molecules. Around 160 grants a month, each with the patent number, title, applicant, inventor names, and full abstract. Unlike published applications (which reveal in-progress research), grants are enforceable rights and signal what a company can now litigate or license. Watch this if you run an antibody or protein biologics program, advise on patent portfolio strategy for biologics companies, scout for licensing opportunities on recently granted claims, or track which research institutions are converting their early peptide work into issued patents.
What changed
USPTO issued Patent US12612451B2 to Alexion Pharmaceuticals, Inc. for a method of treating neuromyelitis optica spectrum disorder (NMOSD) by administering an anti-C5 antibody or antigen-binding fragment. The patent contains 20 claims and lists four inventors: Kerstin Allen, Marcus Yountz, Stephan Ortiz, and Fanny O'Brien.
For competitors in the complement-inhibitor or neurology/biotech space, this grant establishes intellectual property protection around anti-C5 antibody therapies for NMOSD. Companies developing similar complement-inhibitor approaches for NMOSD or related autoimmune conditions should conduct freedom-to-operate analyses and review the patent's claim scope for potential licensing or design-around opportunities.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of treating neuromyelitis optica spectrum disorder (NMOSD) comprising administering an anti-C5 antibody
Grant US12612451B2 Kind: B2 Apr 28, 2026
Assignee
Alexion Pharmaceuticals, Inc.
Inventors
Kerstin Allen, Marcus Yountz, Stephan Ortiz, Fanny O'Brien
Abstract
Provided are methods for clinical treatment of neuromyelitis optica spectrum disorder (NMOSD) using an anti-C5 antibody, or antigen binding fragment thereof.
CPC Classifications
C07K 16/18 C07K 2317/24 C07K 2317/565 C07K 2317/52 C07K 2317/94 C07K 2317/76 C07K 2317/56 A61K 31/436 A61K 31/519 A61K 31/52 A61K 31/5377 A61K 39/3955 A61K 2039/505 A61K 2039/54 A61K 2039/545 A61K 2039/55 A61P 25/00 A61P 37/06
Filing Date
2020-12-08
Application No.
17783106
Claims
20
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.